Shanhu Hu
Papers
1
Total Citations
49
H-Index
1
About
Shanhu Hu is a cancer biologist whose research focuses on cell cycle regulation and the development of next-generation targeted therapies. His key contributions center on cyclin-dependent kinase (CDK) inhibitors and the novel mechanism of anaphase catastrophe—a form of cell death triggered by aberrant mitotic division. In his highly cited 2016 study (49 citations), Hu investigated CCT68127, a potent CDK2/9 inhibitor, demonstrating its superior efficacy over first-generation drugs like seliciclib in inducing multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes. This work provided critical mechanistic insight into how selective CDK2/9 blockade exploits centrosome amplification—a common feature in aggressive tumors—to trigger mitotic catastrophe. By elucidating the molecular pathways linking CDK inhibition to anaphase failure, Hu’s research has advanced the rational design of targeted cancer therapeutics, offering a promising strategy for treating lung cancers resistant to conventional chemotherapy. His findings continue to inform preclinical development of CDK inhibitors with improved selectivity and reduced toxicity.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016